Aptus Capital Advisors’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $169K | Hold |
2,038
| – | – | ﹤0.01% | 970 |
|
|
2025
Q1 | $165K | Buy |
2,038
+1,572
| +337% | +$127K | ﹤0.01% | 923 |
|
|
2024
Q4 | $41.9K | Sell |
466
-235
| -34% | -$21.1K | ﹤0.01% | 1123 |
|
|
2024
Q3 | $69.3K | Hold |
701
| – | – | ﹤0.01% | 891 |
|
|
2024
Q2 | $65K | Sell |
701
-64
| -8% | -$5.93K | ﹤0.01% | 865 |
|
|
2024
Q1 | $72.6K | Buy |
765
+2
| +0.3% | +$190 | ﹤0.01% | 853 |
|
|
2023
Q4 | $68.1K | Sell |
763
-1,015
| -57% | -$90.6K | ﹤0.01% | 647 |
|
|
2023
Q3 | $130K | Buy |
1,778
+313
| +21% | +$22.9K | ﹤0.01% | 597 |
|
|
2023
Q2 | $122K | Sell |
1,465
-25
| -2% | -$2.08K | ﹤0.01% | 507 |
|
|
2023
Q1 | $114K | Buy |
1,490
+794
| +114% | +$60.5K | ﹤0.01% | 508 |
|
|
2022
Q4 | $57.8K | Hold |
696
| – | – | ﹤0.01% | 581 |
|
|
2022
Q3 | $55K | Buy |
696
+251
| +56% | +$19.8K | ﹤0.01% | 544 |
|
|
2022
Q2 | $33K | Hold |
445
| – | – | ﹤0.01% | 496 |
|
|
2022
Q1 | $40K | Buy |
445
+82
| +23% | +$7.37K | ﹤0.01% | 516 |
|
|
2021
Q4 | $41K | Buy |
+363
| New | +$41K | ﹤0.01% | 428 |
|